More ASH.
hematology.org
THE AMERICAN SOCIETY OF HEMATOLOGY
41ST ANNUAL MEETING AND EXPOSITION
December 3-7, 1999
Ernest N. Morial Convention Center
New Orleans, Louisiana
(1999 Meeting Schedule) (Abstract Submission) (General Information)
(Education Program) (Scientific Program) (Special Lectures) (Meet-the-Expert) (Corporate Friday)
(Neville Brothers Performance) (On-line Registration) (Printable Registration Form) (Hotel Reservation Information)
1999 Scientific Subcommittee Program
John M. Harlan, M.D., 1999 Scientific Program Chair, University of Washington, Seattle, WA
The 1999 Scientific Subcommittee Program will be held Saturday December 4, and Sunday,
December 5. Each session will be offered once. Invited abstracts of these sessions will be
published in the supplement to Blood: Journal of the American Society of Hematology.
Scientific Subcommittee on Clinical Laboratory Hematology
Disorders of Hemostasis and Thrombosis: Molecular Mechanisms
Sunday, December 5th, 8:15-10:00 a.m.
Chair:
A. Koneti Rao, M.D., Temple University School of Medicine, Philadelphia, PA
Speakers:
David Ginsburg, M.D., Howard Hughes Medical Institute, University of Michigan Medical
School, Ann Arbor, MI
Molecular Genetics of Combined Deficiency of Coagulation Factors V and VIII
A. Koneti Rao, M.D., Temple University School of Medicine, Philadelphia, PA
Mechanisms of Signal Transduction Defects in Platelets
Mortimer Poncz, M.D., Children?s Hospital of Philadelphia, Philadelphia, PA
Heparin-Induced Thrombocytopenia: New Insights into Mechanisms
Joel L. Moake, M.D., Baylor College of Medicine and Rice University, Houston, TX
Thrombotic Thrombocytopenic Purpura: Clues from Clumps
Scientific Subcommittee on Hematopoietic Growth Factors
Extrinsic Manipulation of Stem Cell Fate
Sunday, December 5th, 10:30 a.m.-12:15 p.m.
Chair:
Connie Eaves, Ph.D., Terry Fox Laboratory, British Columbia Cancer Agency, and University
of British Columbia, Vancouver, British Columbia, Canada
Speakers:
Randall Moon, Ph.D., University of Washington, Howard Hughes Medical Institute, Seattle, WA
WNT Signaling and Specification of Cell Fate
Irwin D. Bernstein, M.D., Fred Hutchinson Cancer Research Center, Seattle, WA
Exploring the Role of Notch in Hematopoiesis
Connie Eaves, Ph.D., Terry Fox Laboratory, British Columbia Cancer Agency, and University
of British Columbia, Vancouver, British Columbia, Canada
Cytokine Control of Normal and Leukemic Stem Cell Self-Renewal
Scientific Subcommittee on Hemoglobin/Red Cell
The Human a -Globin Gene Cluster Revisited
Sunday, December 5th, 8:15-10:00 a.m.
Chair:
George F. Atweh, M.D., Mount Sinai School of Medicine, New York, NY
Speakers:
Doug Higgs, M.D., John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
Regulation of a-Globin Expression: Lessons from the X-Linked a-Thalassemia/Mental Retardation ATRX
Syndrome
Sir David Weatherall, M.D., John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
a-Thalassemia and the Susceptibility to Malaria
Deborah Rund, M.D., Hadassah Ein Kerem, Jerusalem, Israel
a-Thalassemia: Unexpected Geographic Prevalence and Genotypic Diversity
Stephen A. Liebhaber, M.D., Howard Hughes Medical Institute, University of Pennsylvania School of Medicine,
Philadelphia, PA
Developmental Switching in the a-Globin Gene Cluster: Mechanisms and Functions
George F. Atweh, M.D., Mount Sinai School of Medicine, New York, NY
Activity of the HS-40 Regulatory Element: New Insights from Retroviral Gene Transfer Experiments
Scientific Subcommittee on Hemostasis
Cell Surface Signaling in the Regulation of Hemostasis
Saturday, December 4th, 4:00-5:45 p.m.
Chair:
Zaverio M. Ruggeri, M.D., The Scripps Research Institute, La Jolla, CA
Speakers:
Samuel A. Santoro, M.D., Ph.D., Washington University School of Medicine, St. Louis, MO
Signaling Through Collagen Receptors
Peter J. Newman, Ph.D., Blood Center of Southeastern Wisconsin, Milwaukee, WI
PECAM-1 as an Inhibitory Receptor in Blood and Vascular Cells
Wolfram Ruf, M.D., The Scripps Research Institute, La Jolla, CA
Tissue Factor Signaling in Hemostasis
Charles T. Esmon, Ph.D., Howard Hughes Medical Institute, Oklahoma Medical Research Foundation, Oklahoma
City, OK
Endothelial Cell Protein C Receptor
Scientific Subcommittee on Iron and Heme
Iron and Heme: Our Friends and Foes
Saturday, December 4th, 1:45-3:30 p.m.
Chair:
Prem Ponka, M.D., Ph.D., Lady Davis Institute for Medical Research, Jewish General Hospital/McGill
University, Montreal, Quebec, Canada
Speakers:
Tracey Rouault, M.D., National Institute of Child Health and Human Development, Bethesda, MD
Targeted Disruption of Iron Regulatory Protein 2 in Mice Leads to Neuronal Iron Overload and Progressive
Neurodegeneration
Jonathan D. Gitlin, M.D., Washington University School of Medicine, St. Louis, MO
Aceruloplasminemia: An Essential Role for Ceruloplasmin in Cellular Iron Efflux
Mark Fleming, M.D., D.Phil., Children?s Hospital, Boston, MA
The Siderocytic Anemia of Flexed-Tail Mice
Gregory M. Vercellotti, MD, University of Minnesota Medical School, Minneapolis, MN
Heme and the Vasculature: The Endothelium?s Jekyll and Hyde Response
Scientific Subcommittee on Lymphocyte Biology
Cellular Immunotherapy For Treatment of Hematologic Malignancies
Sunday, December 5th, 10:30 a.m.-12:15 p.m.
Chair:
Oliver W. Press, M.D., Ph.D., University of Washington Medical Center, Seattle, WA
Speakers:
Craig B. Thompson, M.D., Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia,
PA
Inhibitory Pathways That Terminate Immune Responses In Vivo: Implications for the Development of Cellular
Immunotherapies
Carl H. June, M.D., University of Pennsylvania, Philadelphia, PA
Adoptive Immunotherapy With Co-Stimulated Autologous Lymphocytes
John M. Goldman, D.M., Imperial College School of Medicine at Hammersmith Hospital, London, United
Kingdom
Donor Lymphocyte Infusion for Chronic Myelogenous Leukemia
Stanley R. Riddell, M.D., Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Future Prospects for Cellular Immunotherapy of Cancer
Scientific Subcommittee on Myeloid Biology
New Insights Into the Role of Transcription Factor Interactions in Hematopoietic Lineage
Development
Saturday, December 4th, 1:45-3:30 p.m.
Chair:
Daniel G. Tenen, M.D., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Speakers:
Stuart H. Orkin, M.D., Children?s Hospital, Howard Hughes Medical Institute, Boston, MA
Modulation of GATA Factors by Interacting Proteins
Terence Rabbitts, B.Sc., Ph.D., MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
Transcription Factor Interactions That Influence Hematopoiesis and Leukemia
Christopher Glass, M.D., Ph.D., University of California, San Diego, La Jolla, CA
Coactivator and Corepressor Complexes as Integrators of Multiple Signaling Pathways
Daniel G. Tenen, M.D., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Positive and Negative Regulators of the PU.1 Transcription Factor Interact With a Common Domain
Scientific Subcommittee on Neoplasia
Mouse Models of Leukemia and Lymphoma
Saturday, December 4th, 1:45-3:30 p.m.
Chair:
Stanton L. Gerson, M.D., Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve
University, Cleveland, OH
Speakers:
Stanton L. Gerson, M.D., Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve
University, Cleveland, OH
DNA Repair Defects: Pathways to Murine Lymphomas and Treatment-Related Leukemias
Pier Paolo Pandolfi, M.D, Ph.D., Memorial Sloan-Kettering Cancer Center, New York, NY
Transgenic Expression of RAR: PML - A Mouse Model of Human APL
Richard A. Van Etten, M.D., Ph.D., Harvard Medical School, Boston, MA
Pathogenesis of Philadelphia-Positive Leukemia: Insights from Mouse Model Systems
Michael Cleary, M.D., Stanford University, Stanford, CA
Mouse Models for Pbx-Hox Function in Leukemogenesis and Hematopoiesis
Scientific Subcommittee on Pediatric Hematology
Genetic Modifiers of Severity of Inherited Hematologic Diseases
Sunday, December 5th, 8:15-10:00 a.m.
Chair:
George Dover, M.D., Johns Hopkins Hospital, Baltimore, MD
Speakers:
Stephen Chanock, M.D., National Cancer Institute, Bethesda, MD
Genetic Modifiers of Severity of Chronic Granulomatous Disease
David H.K. Chui, M.D., McMaster University Medical Center, Hamilton, Ontario, Canada
Genetic Modifiers of Hemoglobinopathies
Randal J. Kaufman, Ph.D., Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor,
MI
Genetic Modifiers of Hemophilia and von Willebrand?s Disease
Scientific Subcommittee on Platelets
Mechanisms of Platelet Adhesion
Sunday, December 5th, 10:30 a.m.-12:15 p.m.
Chair:
Samuel A. Burstein, M.D., University of Oklahoma, Oklahoma City, OK
Speakers:
Paul S. Frenette, M.D., Mount Sinai School of Medicine, New York, NY
Adhesive Events Mediating Platelet-Endothelial Interactions
Zaverio M. Ruggeri, M.D., The Scripps Research Institute, La Jolla, CA
Initiation and Propagation of Platelet Adhesion and Aggregation
Jan J. Sixma, M.D., University Hospital Utrecht, Utrecht, The Netherlands
Adhesion and Thrombus Formation in Flow: Role of Collagen
Thomas J. Kunicki, Ph.D., The Scripps Research Institute, La Jolla, CA
The Clinical Impact of Inherited Modulation of Platelet Adhesion
Scientific Subcommittee on Thrombosis & Vascular Biology
Genomics Tools for Studying Thrombosis and Vascular Disease
Saturday, December 4th, 4:00-5:45 p.m.
Chair:
Barbara C. Furie, Ph.D., Beth Israel Deaconess Medical Center, Boston, MA
Speakers:
David Ginsburg, M.D., Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI
Mouse Model of von Willebrand Factor Deficiency: Characterization of a Modifying Gene
Edwin Bovill, M.D., University of Vermont College of Medicine, Burlington, VT
Thrombophilia: A Model of Multigenic Disease
Richard Lifton M.D., Ph.D., Yale University School of Medicine, New Haven CT
Molecular Genetics of Hypertension: Impact of the Kidneys on the Vasculature
Scientific Subcommittee on Transfusion Medicine
Support of the Thrombocytopenic Patient
Sunday, December 5th, 10:30 a.m.-12:15 p.m.
Chair:
Thomas H. Price, M.D., Puget Sound Blood Center, Seattle, WA
Speakers:
David J. Kuter, M.D., D.Phil., Massachusetts General Hospital, Boston, MA
Stimulation of Platelet Production ? Clinical Experience
William Sheridan, M.B., B.S., FRACP, Amgen Inc., Thousand Oaks, CA, and UCLA School of Medicine, Los
Angeles, CA
Platelet Dose
Morris Blajchman, M.D., McMaster University Medical Center, Hamilton, Ontario, Canada
Platelet Substitutes
Scientific Subcommittee on Transplantation Biology
Induction of Mixed Chimerism by Allogeneic Hematopoietic Cell Transplantation
Saturday, December 4th, 4:00-5:45 p.m.
Chair:
Karl G. Blume, M.D., Stanford University, Stanford, CA
Speakers:
Karl G. Blume, M.D., Stanford University, Stanford, CA
Introduction: Mixed Chimerism
Samuel Strober, M.D., Stanford University, Palo Alto, CA
Which T Cells Are Needed for Engraftment and Graft-Versus-Tumor Effect?
Megan Sykes, M.D., Harvard Medical School, Boston, MA
From Murine Models of Chimerism to Clinical Transplantation
Rainer F. Storb, M.D., Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
Mixed Chimerism and Graft-Versus-Tumor Effect ? A Curative Concept Derived from the Dog Model
|
